The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | An overview of the promising upcoming therapies for patients with LR-MDS
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of promising new therapies for patients with lower-risk myelodysplastic syndromes (LR-MDS), who are primarily treated for cytopenia and anemia. Imetelstat, a first-in-class telomerase inhibitor, has demonstrated significant improvements in hemoglobin levels, representing a shift away from hypomethylating agent-based therapies, which are known for their higher toxicity. Furthermore, ongoing studies are exploring the use of inflammasome inhibitors to target the underlying pathogenic mechanisms of LR-MDS. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
